Cost-Effectiveness of Routine Screening for Cardiac Toxicity in Patients Treated with Imatinib in Brazil.

[1]  M. Marcolino,et al.  The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients , 2011, Hematological oncology.

[2]  D. Sawyer,et al.  Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage , 2010, Current hypertension reports.

[3]  M. Minami,et al.  Cardiovascular side-effects of modern cancer therapy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[4]  J. Plana,et al.  Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate , 2009, Cancer.

[5]  H. Kantarjian,et al.  Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. , 2009, Leukemia research.

[6]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[7]  A. Ardavanis,et al.  Cardiotoxicity induced by tyrosine kinase inhibitors , 2009, Acta oncologica.

[8]  A. Ribeiro,et al.  An evaluation of the cardiotoxicity of imatinib mesylate. , 2008, Leukemia research.

[9]  A. Frustaci,et al.  Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. , 2008, Leukemia research.

[10]  Marcos Bossi Ferraz,et al.  Internações por pé diabético: comparação entre o custo direto estimado e o desembolso do SUS , 2008 .

[11]  Sulamis Dain.  Os vários mundos do financiamento da Saúde no Brasil: uma tentativa de integração , 2007 .

[12]  J. Blay,et al.  Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. , 2007, European journal of cancer.

[13]  Yeon-Hee Park,et al.  BNP as a marker of the heart failure in the treatment of imatinib mesylate. , 2006, Cancer letters.

[14]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[15]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[16]  J. Blay,et al.  Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[17]  D. Gary Gilliland,et al.  The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management , 2004 .

[18]  D. Faxon,et al.  ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca , 2003, Journal of the American College of Cardiology.

[19]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[20]  R. Clark,et al.  A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. , 2011, Leukemia research.

[21]  J. Melo,et al.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. , 2007, Blood.

[22]  T. Force.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[23]  Pamela S Douglas,et al.  Acc/aha/ase 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines (acc/aha/ase Committee to Update the 1997 Guidelines for the Clinical Application of Echocar , 2003 .